Denali Therapeutics Inc. (DNLI) Tops Q3 EPS by 1c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q3 EPS of ($0.74), $0.01 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Walmart adds Apple Pay as retailer expands contactless payments
• UDynamics files for Nasdaq IPO of 5.6 million shares at $5-$7 per share